Form 4: Silexion Director Abramov Reports Equity Grants
Insider Transaction Report
Silexion Therapeutics Director Dror Yosef Abramov reported the grant of 794 ordinary shares as RSUs and 935 stock options, with all figures adjusted for recent reverse stock splits.
Summary
- Director Dror Yosef Abramov reported the acquisition of 794 ordinary shares in the form of Restricted Stock Units (RSUs) on February 9, 2025.
- These RSUs were granted at a price of $0 and are scheduled to vest in full on February 9, 2026, contingent on Mr. Abramov's continued service.
- Mr. Abramov also reported the acquisition of 935 stock options on February 9, 2025, with an exercise price of $18.9 per share.
- These stock options become exercisable on February 9, 2026, and have an expiration date of February 9, 2035.
- All reported share and option numbers, as well as the option exercise price, have been retroactively adjusted to reflect a 1-for-15 reverse share split effected by Silexion Therapeutics Corp on July 29, 2025.
- An informational entry for 295 ordinary shares was included, which had been adjusted for a 1-for-9 reverse share split on November 29, 2024, and the 1-for-15 reverse share split on July 29, 2025.
Sentiment
Score: 5
Explanation: The filing is a mandatory disclosure of insider equity transactions and does not contain information that would significantly alter the company's fundamental sentiment, beyond the inherent implications of equity grants and reverse splits.
Positives
- The grant of equity (RSUs and stock options) to a director aligns management's interests with those of shareholders.
- The vesting schedule for RSUs and exercisability for options encourages long-term commitment from the director.
Negatives
- The filing itself does not contain explicit negative information, but it notes adjustments due to multiple reverse stock splits (1-for-9 on November 29, 2024, and 1-for-15 on July 29, 2025), which can often indicate challenges with share price or capital structure.
Risks
- The value of the granted RSUs and stock options is subject to the future performance of Silexion Therapeutics Corp's stock price.
- Continued service is required for the RSUs to vest, posing a risk of forfeiture if the director's service terminates prematurely.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Director Dror J. Abramov granted a Power of Attorney to Mirit Horenshtein Hadar, the Chief Financial Officer, authorizing her to prepare, execute, and file Forms 3, 4, and 5 with the SEC on his behalf. | 2024-08-15 | Streamlines compliance with Section 16(a) of the Securities Exchange Act of 1934 for the reporting person, ensuring timely and accurate insider transaction disclosures. |
Related Party Transactions
- Grant of 794 Restricted Stock Units (RSUs) to Director Dror Yosef Abramov.
- Grant of 935 stock options to Director Dror Yosef Abramov.
Stakeholder Impact
- Shareholders: The equity grants align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value. The reverse stock splits, while adjustments in this filing, could impact shareholder perception and liquidity.
- Employees: The filing does not directly impact employees, but the director's continued service is a condition for RSU vesting.
Next Steps
- Continued service of Director Dror Yosef Abramov for RSU vesting.
- Vesting of 794 Ordinary Shares (RSUs) on February 9, 2026.
- Potential exercise of 935 stock options between February 9, 2026, and February 9, 2035.
Key Dates
| Date | Description |
|---|---|
| 2024-08-15 | Date Dror J. Abramov executed the Power of Attorney granting Mirit Horenshtein Hadar authority to file SEC forms. |
| 2024-11-29 | Effective date of a 1-for-9 reverse share split by Silexion Therapeutics Corp. |
| 2025-02-09 | Transaction date for the grant of 794 Ordinary Shares (RSUs) and 935 Stock Options to Director Dror Yosef Abramov. |
| 2025-07-29 | Effective date of a 1-for-15 reverse share split by Silexion Therapeutics Corp. |
| 2025-12-31 | Date the Form 4 was signed by the attorney-in-fact. |
| 2026-02-09 | Date when the 794 Ordinary Shares (RSUs) are scheduled to vest in full, and when the 935 stock options become exercisable. |
| 2035-02-09 | Expiration date of the 935 stock options. |
Keywords
Silexion Therapeutics Corp, SLXN, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Reverse Stock Split, Director Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.